# Trial to Assess Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents

> **NCT02212457** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 1063 (actual)

## Conditions studied

- Infections, Meningococcal

## Interventions

- **BIOLOGICAL:** Bexsero
- **OTHER:** Saline Placebo
- **BIOLOGICAL:** Havrix
- **BIOLOGICAL:** MenABCWY

## Key facts

- **NCT ID:** NCT02212457
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08-21
- **Primary completion:** 2015-05-22
- **Final completion:** 2016-03-03
- **Target enrollment:** 1063 (ACTUAL)
- **Last updated:** 2019-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02212457

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02212457, "Trial to Assess Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02212457. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*